DDInter1055 DDInter1925
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) downregulates {v} (Gene) SDC1
SDC1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Levofloxacin {u} (Compound) resembles {v} (Compound) Ofloxacin
Ofloxacin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is regulated by {v} (Gene) SATB1
SATB1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is regulated by {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Levofloxacin (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Vemurafenib (Compound)
Levofloxacin (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is upregulated by Vemurafenib (Compound)
Levofloxacin (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Vemurafenib (Compound)
Levofloxacin (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Vemurafenib
Levofloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may lead to a major life threatening interaction when taken with Vemurafenib
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Levofloxacin (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is regulated by SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)
Levofloxacin (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is regulated by ORM1 (Gene) and ORM1 (Gene) is bound by Vemurafenib (Compound)